We recently encountered a drug name confusion with an even higher potential for acutely catastrophic effects than the commonly cited Levoxine-Lanoxin confusion.1 A 60-year-old woman with atrial fibrillation (heart rate, 140-160/min) suffered a non–Q wave myocardial infarction in the intensive care unit (ICU) following emergency surgery for a superior mesenteric artery embolism. Attempts to induce sinus rhythm to improve her cardiac function failed despite the administration of intravenous procainamide hydrochloride and 2 attempts at electrocardioversion. Since the patient was taking nothing by mouth, a cardiology consultant prescribed intravenous amiodarone. Because the patient was not in the cardiac ICU, the nursing staff had no experience with amiodarone. They were, however, very familiar with amrinone, which was ward stock in their unit. Therefore, it was assumed that the physician's order read amrinone. Approximately 250 mg of amrinone was administered during the 4 hours before the pharmacy received the prescription and detected the medication error. The patient suffered from chest pain and tachycardia, but no permanent adverse effects were detected.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.